Dehydroepiandrosterone supplementation in assisted reproduction: rationale and resultsMamas, Leonidas; Mamas, EudoxiaCurrent Opinion in Obstetrics and Gynecology: August 2009 - Volume 21 - Issue 4 - p 306–308 doi: 10.1097/GCO.0b013e32832e0785 Reproductive endocrinology: Edited by David L. Olive Abstract Author InformationAuthors Article MetricsMetrics Purpose of review To present the possible positive effect of dehydroepiandrosterone administration in assisted reproduction and especially in poor responders, women with diminished ovarian reserve, premature ovarian failure and premature ovarian aging in the course of ovarian stimulation protocols followed either by intrauterine insemination or IVF. Recent findings Overall, 50–75 mg of dehydroepiandrosterone supplementation for at least 4 months may either result in natural conception or considerably improves intrauterine insemination and IVF outcome and pregnancy rates to women with confirmed diminished ovarian reserve, premature ovarian failure or premature ovarian aging. Positive effect has been reported to oocyte and embryo quality, even to women aged 40–47 years. The number of euploid embryos is increased, and miscarriage rate is decreased. Summary Although more data on the dehydroepiandrosterone effect on assisted reproduction are needed, results obtained over the last few years confirm the improvement of oocyte production and pregnancy rates. No significant side effects are reported, and those include mainly hirstusism and acne. Neogenesis IVF Centre, Athens, Greece Correspondence to Leonidas Mamas, 3 Kifissias Av., 15123 Marousi, Athens, Greece Tel: +30 210 6828150/1/2; fax: +30 210 6836090; e-mail: firstname.lastname@example.org © 2009 Lippincott Williams & Wilkins, Inc.